The ultimate success of the Bristol-Myers’ Celgene purchase could hinge on one upcoming trial

Biggest life sciences M&A deal for nearly two decades may turn out to be a damp squib if Dr Reddy’s wins a suit relating to follow-on patents that cover flagship cancer treatment Revlimid

Unlock unlimited access to all IAM content